AbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® +...
(Source: AbbVie Inc) - RUBY-I evaluates treatment-naïve, non-cirrhotic, genotype 1 chronic hepatitis C patients with severe renal impairment - In preliminary data from RUBY-I, patients receiving...
View ArticleAbbVie Announces High SVR Rates with VIEKIRAX®...
BARCELONA, Spain, April 14, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced data showing that patients with genotype 1 (GT1) chronic hepatitis C virus...
View ArticleViiV Healthcare announces phase II study results for first two drug,...
(Source: GSK - GlaxoSmithKline plc) 32 week maintenance data presented at CROI showed comparable viral suppression rates between injectable regimen and three drug oral regimen Issued: London London,...
View ArticleFirst Regimen Combining Long Acting Injectable Antiretrovirals; 32-Week LATTE...
(Source: Johnson & Johnson) Intramuscular 2-drug maintenance therapy demonstrates comparable antiviral activity to daily oral 3-drug combination CORK, Ireland, - February 24, 2016 - Janssen...
View ArticleViiV Healthcare begins phase III programme with dolutegravir/rilpivirine...
(Source: GSK - GlaxoSmithKline plc) 06 May 2015 First programme to evaluate dual HIV maintenance therapy with dolutegravir and rilpivirine London, United Kingdom, 6 May 2015: ViiV Healthcare today...
View ArticleViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine...
First programme to evaluate dual HIV maintenance therapy with dolutegravir and rilpivirine LONDON, May 6, 2015 /CNW/ - ViiV Healthcare today announced the start of a Phase III clinical trial programme...
View ArticleJanssen to Progress Collaboration with ViiV Healthcare to Develop the First...
(Source: Johnson & Johnson) 5bdf0770-87c8-4b68-992a-859cfe2ae0b0.pdf January 7, 2016 Janssen to Progress Collaboration with ViiV Healthcare to Develop the First Long Acting Two Drug Injectable...
View ArticleFirst Investigational All Injectable Long Acting HIV Combination Regimen...
(Source: Johnson & Johnson) 4276210d-1972-426f-bab1-761478e35fc7.pdf November 3, 2015 First Investigational All Injectable Long Acting HIV Combination Regimen Study Results at 32 Weeks Announced...
View ArticleU.S. Food and Drug Administration Approves Gilead’s Single Tablet Regimen...
(Source: Gilead Sciences Inc) – Gilead’s First TAF-based Regimen Demonstrates High Efficacy with Improved Renal and Bone Parameters Compared to TDF-based Regimens – FOSTER CITY, Calif.--(BUSINESS...
View ArticleEuropean Commission Approves Bristol-Myers Squibb’s Evotaz (atazanavir and...
(Source: Bristol-Myers Squibb Company) The European Commission approval is based upon Phase III clinical trial - Reyataz®(atazanavir) and cobicistat combination demonstrated virologic failure rates as...
View ArticleLupin Bolsters US Brands Portfolio with Methergine® Oral Tablets
MUMBAI, India and BALTIMORE, April 28, 2016 /PRNewswire/ -- The only FDA-approved oral uterotonic for the management of PPH, comes to market with a significant investment in professional medical...
View ArticleBristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for...
(Source: Bristol-Myers Squibb Company) BMS-663068 is the first investigational antiretroviral designed to prevent HIV attachment to and entry into CD4+ T cells FDA Breakthrough Designation recognizes...
View ArticleOLYSIO® (simeprevir) Gains Additional FDA Approval as Once-Daily, All-Oral...
OLYSIO(R) (simeprevir) Logo Facebook Twitter Pinterest OLYSIO(R) (simeprevir) bottle Facebook Twitter Pinterest Janssen Logo Facebook Twitter Pinterest × OLYSIO(R) (simeprevir) Logo OLYSIO(R)...
View ArticleJanssen Highlights its Hepatitis C Clinical Development Program in Advance of...
Janssen Logo. Facebook Twitter Pinterest × Janssen Logo. BOSTON, Nov. 7, 2014 /PRNewswire/ -- Janssen R&D Ireland (Janssen) highlights its hepatitis C (HCV) clinical development program in advance...
View ArticleJanssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral,...
(Source: Johnson & Johnson) July 23, 2015 Janssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral, Once-Daily OLYSIO® (Simeprevir) in Combination with Sofosbuvir Filing Supported...
View ArticleJanssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral,...
TITUSVILLE, N.J., July 23, 2015 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced the submission of a supplemental New Drug Application (sNDA) to the...
View ArticleJanssen Announces Collaboration with Gilead to Develop PREZISTA®-based...
-- Two Companies to also Collaborate on the Further Development of Complera®, Marketed as Eviplera® in the European Union -- CORK, Ireland, Dec. 29, 2014 /CNW/ - Janssen R&D Ireland (Janssen)...
View ArticleJanssen Announces Collaboration with Gilead to Develop PREZISTA®-based...
Janssen Logo. (PRNewsFoto/Janssen Pharmaceutical Companies) Facebook Twitter Pinterest × Janssen Logo. (PRNewsFoto/Janssen Pharmaceutical Companies) CORK, Ireland, December 29, 2014 /PRNewswire/ -- --...
View ArticlePREZCOBIX™ (darunavir/cobicistat) Approved in the U.S. for the Treatment of...
PREZCOBIX(TM) (darunavir 800mg / cobicistat 150mg) Tablets Facebook Twitter Pinterest PREZCOBIX(TM) (darunavir 800mg / cobicistat 150mg) Bottle Facebook Twitter Pinterest PREZCOBIX(TM) Logo Facebook...
View ArticleYour Story, Your HIV Wisdom™ Brings Together HIV Voices and Supports HIV...
(Source: Johnson & Johnson) Notable HIV Advocates Highlight Perspectives of People Living with or Affected by HIV to Leverage Shared Support and Self-Expression TITUSVILLE, N.J., September 8, 2015...
View Article